By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Why New Standards Are Needed for Faster Cancer Drug Approvals
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Why New Standards Are Needed for Faster Cancer Drug Approvals
Policy & LawPublic Health

Why New Standards Are Needed for Faster Cancer Drug Approvals

Andrew Schorr
Andrew Schorr
Share
4 Min Read
SHARE

Several years ago I attended an FDA Oncology Drug Advisory Committee (ODAC) hearing. What the medical experts and the FDA regulators wanted to know most was did a proposed new cancer medicine help people live longer? Not better, just longer.

Several years ago I attended an FDA Oncology Drug Advisory Committee (ODAC) hearing. What the medical experts and the FDA regulators wanted to know most was did a proposed new cancer medicine help people live longer? Not better, just longer. The CLL (chronic lymphocytic leukemia) drug in question that day was not recommended for approval because they never could show a “survival advantage.” I think the small biotech that made the drug ended up being closed down. Fortunately, the FDA has approved some other cancer drugs since then where they’ve helped people live better. I take one, Jakafi for myelofibrosis, which greatly reduces symptoms but there’s no clear data yet that people live longer because of it. So thanks to the FDA for becoming more enlightened. But now there’s a need to move still further ahead.

In some cancer conditions people are living for many years with cancer before they eventually succumb. Biochemically recurrent prostate cancer can be like that. There’s evidence the cancer has spread but it’s not obvious where. Another case is in CLL where people with less aggressive subtypes may have had treatment but then be in remission for several years. So here’s the regulatory problem: if people are going to live several or many years with a cancer, how can you early on a measure the effectiveness of a proposed new drug that might help them live longer? In prostate cancer and CLL, to name two examples, that’s the dilemma. There may be a “survival advantage,” for example for one of these promising new “small molecule” pills now in trials, or even a new drug that’s been approved, as in prostate cancer. But you need a test the FDA and other regulatory bodies will accept as a “surrogate” for how long someone lives.

In an interview with Dr. Celestia Higano, a prostate cancer expert, she tells me about just that. And in another interview, with Dr. Peter Hillmen, a CLL expert, he said he is going before the FDA to ask that sensitive tests for MRD (minimal residual disease) be acceptable measures. The idea is new tests, or ones that should be developed, can be an acceptable measure of whether a potential new drug will extend life.

More Read

Inpatient vs. Outpatient Drug Recovery — Which One Works?
Don’t Let Paperwork Get in the Way of Your Work’s Purpose
Can Medical Error Victims Sue the Responsible Parties For Medical Malpractice?
What’s at the End of the Road to Cost Transparency? 5 Fresh Ideas on the Future of Healthcare
Florida House Passes Medicaid Privatization Plan

My view is the FDA, and other agencies around the world, should work collaboratively with industry and scientists to expeditiously assess if a potential new drug is worth approval. If new tests can speed things up then let’s agree on them and use them.

As some cancers are now becoming more like chronic conditions where you live with them rather than dying fairly quickly from them, we need a new system to measure how lasting “chronic” is.

TAGGED:cancerdrug approvalFDA
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Trust Is What Makes Health Care Work: A Success Story from Belgium

October 14, 2013
Health careWellness

What Is More Effective: Fighting Depression Or Denying It?

May 6, 2019
BusinessPolicy & Law

How Much Does A Colonoscopy Cost?

August 12, 2012
Health carePublic Health

Private Health Insurance Approach Inspires International Changes

September 30, 2019
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?